ES2176359T3 - Liberacion localizada de factores que favorecen la supervivencia de celulas transplantadas. - Google Patents

Liberacion localizada de factores que favorecen la supervivencia de celulas transplantadas.

Info

Publication number
ES2176359T3
ES2176359T3 ES95943823T ES95943823T ES2176359T3 ES 2176359 T3 ES2176359 T3 ES 2176359T3 ES 95943823 T ES95943823 T ES 95943823T ES 95943823 T ES95943823 T ES 95943823T ES 2176359 T3 ES2176359 T3 ES 2176359T3
Authority
ES
Spain
Prior art keywords
egf
survival
microspheres
factors
hepatocits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95943823T
Other languages
English (en)
Inventor
David J Mooney
Robert S Langer
Joseph P Vacanti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Massachusetts Institute of Technology
Original Assignee
Boston Childrens Hospital
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital, Massachusetts Institute of Technology filed Critical Boston Childrens Hospital
Application granted granted Critical
Publication of ES2176359T3 publication Critical patent/ES2176359T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Materials For Medical Uses (AREA)

Abstract

SE ADMINISTRAN FACTORES DE CRECIMIENTO Y/O FACTORES ANGIOGENICOS EN COMBINACION CON LAS CELULAS DISOCIADAS A TRASPLANTAR, PREFERENTEMENTE EN MICROESFERAS CON LAS CELULAS ENCIMA O EN UNA MATRIZ POLIMERICA, PARA AUMENTAR LA SUPERVIVENCIA Y PROLIFERACION DE LAS CELULAS TRASPLANTADAS. LOS EJEMPLOS DEMUESTRAN QUE EL FACTOR DE CRECIMIENTO EPIDERMAL (EGF) SE INCORPORO EN MICROESFERAS FABRICADAS A PARTIR DE UN COPOLIMERO DE ACIDO LACTICO O GLICOLICO UTILIZANDO UNA TECNICA DE DOBLE EMULSION, EL EGF INCORPORADO SE LIBERO DE FORMA REGULAR TRAS HABER ESTADO UN MES IN VITRO Y PERMANECIO BIOLOGICAMENTE ACTIVO, PUES SEGUIA TENIENDO SU CAPACIDAD DE ESTIMULAR LA SINTESIS DE ADN, DIVISION Y SUPERVIVENCIA A LARGO PLAZO DE HEPATOCITOS CULTIVADOS. LAS MICROESFERAS QUE CONTENIAN EL EGF SE MEZCLARON CON UNA SUSPENSION DE HEPATOCITOS, SE NUCLEARON SOBRE ESPONJAS POROSAS E IMPLANTARON EN EL MESENTERIO DE DOS GRUPOS DE RATAS LEWIS, PARA DEMOSTRAR LA EFICACIA IN VIVO. DOS SEMANAS DESPUES DE LA IMPLANTACION EN ANIMALES PCS, DISPOSITIVOS QUE INCLUIAN MICROESFERAS QUE CONTENIAN EGF PRESENTABAN UN AUMENTO DOS VECES MAYOR DEL NUMERO DE HEPATOCITOS INJERTADOS, EN COMPARACION A LOS IMPLANTES QUE RECIBIERON MICROESFERAS SOLAS.
ES95943823T 1994-12-16 1995-12-14 Liberacion localizada de factores que favorecen la supervivencia de celulas transplantadas. Expired - Lifetime ES2176359T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/358,235 US6281015B1 (en) 1994-12-16 1994-12-16 Localized delivery of factors enhancing survival of transplanted cells

Publications (1)

Publication Number Publication Date
ES2176359T3 true ES2176359T3 (es) 2002-12-01

Family

ID=23408836

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95943823T Expired - Lifetime ES2176359T3 (es) 1994-12-16 1995-12-14 Liberacion localizada de factores que favorecen la supervivencia de celulas transplantadas.

Country Status (10)

Country Link
US (1) US6281015B1 (es)
EP (1) EP0794790B1 (es)
JP (2) JP4361134B2 (es)
AT (1) ATE216255T1 (es)
CA (1) CA2207286C (es)
DE (1) DE69526448T2 (es)
DK (1) DK0794790T3 (es)
ES (1) ES2176359T3 (es)
PT (1) PT794790E (es)
WO (1) WO1996018411A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
CA2382908A1 (en) * 1999-09-16 2001-03-22 Novo Nordisk A/S Composition for ivf
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU2001245734A1 (en) 2000-03-15 2001-09-24 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US6719970B1 (en) 2000-07-10 2004-04-13 Alkermes Controlled Therapeutics, Inc. Method of generating cartilage
EP1311657A2 (en) * 2000-08-21 2003-05-21 Rice University Tissue engineering scaffolds promoting matrix protein production
DE60131177T2 (de) 2000-09-06 2008-08-07 AP Pharma, Inc., Redwood Abbaubare polyacetal-polymere
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
EP1411861B1 (en) 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20040209360A1 (en) * 2003-04-18 2004-10-21 Keith Steven C. PVA-based polymer coating for cell culture
US20040209361A1 (en) * 2003-04-18 2004-10-21 Hemperly John J. UV-cross-linked PVA-based polymer particles for cell culture
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
WO2009048462A1 (en) 2007-10-09 2009-04-16 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US20050214377A1 (en) * 2004-03-24 2005-09-29 Sanjay Mistry Microparticles for cell delivery
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
TW200605910A (en) * 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
ATE503465T1 (de) 2004-10-25 2011-04-15 Celonova Biosciences Germany Gmbh Beladbare polyphosphazenhaltige teilchen für therapeutische und/oder diagnostische anwendungen sowie herstellungs- und verwendungsverfahren dafür
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
ATE450276T1 (de) * 2004-12-08 2009-12-15 Pervasis Therapeutics Inc Materialien und verfahren zur minimal invasiven abgabe einer zellhaltigen fliessfähigen zusammensetzung
CA2605080A1 (en) * 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
US20060257355A1 (en) * 2005-05-10 2006-11-16 Abiomed, Inc. Impregnated polymer compositions and devices using them
EP2361591A3 (en) * 2005-06-21 2011-12-21 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
KR101338533B1 (ko) 2005-07-19 2013-12-12 스템젠 에스.피.에이. Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생가능성의 억제
EP1948259B1 (en) * 2005-10-26 2017-03-22 Genesis Technologies Limited Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
WO2007146319A2 (en) * 2006-06-13 2007-12-21 Symphony Medical, Inc. Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications
JP5372764B2 (ja) * 2006-11-07 2013-12-18 シャイア リジェネラティブ メディシン， インコーポレイテッド 血管形成関連疾患の治療および管理のための材料および方法
WO2008118919A1 (en) 2007-03-26 2008-10-02 Dexcom, Inc. Analyte sensor
US20200037875A1 (en) 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20080306444A1 (en) 2007-06-08 2008-12-11 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
CA2698212A1 (en) 2007-08-23 2009-02-26 Intrexon Corporation Methods and compositions for diagnosing disease
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
CN102047101A (zh) 2008-03-28 2011-05-04 德克斯康公司 用于连续的分析物传感器的聚合物膜
BRPI0913697A2 (pt) * 2008-09-25 2016-10-11 Invivo Therapeutics Corp lesão de medula, inflamação e doença auto-imuni: agentes teraupêuticos de liberação local controlada.
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
CN102695501A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 碎裂水凝胶
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
EP3575796B1 (en) 2011-04-15 2020-11-11 DexCom, Inc. Advanced analyte sensor calibration and error detection
WO2012176023A1 (en) 2011-06-23 2012-12-27 Indian Institute Of Technology Kanpur Hydrogel scaffolds for tissue engineering
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
US9549692B2 (en) 2011-08-26 2017-01-24 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9381112B1 (en) 2011-10-06 2016-07-05 William Eric Sponsell Bleb drainage device, ophthalmological product and methods
US8632489B1 (en) 2011-12-22 2014-01-21 A. Mateen Ahmed Implantable medical assembly and methods
CN106635949B (zh) * 2011-12-22 2020-05-19 生命技术公司 细胞培养基和方法
US9788765B2 (en) 2012-09-28 2017-10-17 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
CA3002099A1 (en) 2015-12-30 2017-07-06 Dexcom, Inc. Diffusion resistance layer for analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1995970A (en) 1931-04-04 1935-03-26 Du Pont Polymeric lactide resin
US2609347A (en) 1948-05-27 1952-09-02 Wilson Christopher Lumley Method of making expanded polyvinyl alcohol-formaldehyde reaction product and product resulting therefrom
US2664367A (en) 1949-09-19 1953-12-29 Wilson Christopher Lumley Plasticized sponge material and method of making same
US2664366A (en) 1949-09-19 1953-12-29 Wilson Christopher Lumley Plasticized sponge material and method of making same
US2659935A (en) 1950-03-18 1953-11-24 Christopher L Wilson Method of making compressed sponges
US2653917A (en) 1950-06-15 1953-09-29 Christopher L Wilson Method of making an expanded material and the product resulting therefrom
US2676945A (en) 1950-10-18 1954-04-27 Du Pont Condensation polymers of hydroxyacetic acid
US2683136A (en) 1950-10-25 1954-07-06 Du Pont Copolymers of hydroxyacetic acid with other alcohol acids
US2703316A (en) 1951-06-05 1955-03-01 Du Pont Polymers of high melting lactide
US2758987A (en) 1952-06-05 1956-08-14 Du Pont Optically active homopolymers containing but one antipodal species of an alpha-monohydroxy monocarboxylic acid
US2846407A (en) 1954-01-13 1958-08-05 Wilson Christopher Lumley Method of making a detergent and solvent resistant sponge material
DE1228416B (de) 1957-03-04 1966-11-10 Boehringer Sohn Ingelheim Verfahren zur Herstellung von Polyestern
NL280825A (es) 1962-07-11
US3531561A (en) 1965-04-20 1970-09-29 Ethicon Inc Suture preparation
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (es) 1972-01-26 1977-01-27
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4440921A (en) 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4495174A (en) 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
JPS6098823A (ja) 1983-11-02 1985-06-01 株式会社東芝 電力変換装置
US4880622A (en) 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
WO1990009783A1 (en) * 1989-02-22 1990-09-07 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US4946938A (en) 1989-08-01 1990-08-07 The University Of Pittsburgh A process for the catalytic synthesis of polyphosphazenes
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters

Also Published As

Publication number Publication date
EP0794790A1 (en) 1997-09-17
DK0794790T3 (da) 2002-07-22
JP2008011863A (ja) 2008-01-24
DE69526448D1 (de) 2002-05-23
EP0794790B1 (en) 2002-04-17
CA2207286A1 (en) 1996-06-20
DE69526448T2 (de) 2002-11-07
ATE216255T1 (de) 2002-05-15
PT794790E (pt) 2002-09-30
CA2207286C (en) 2003-10-07
WO1996018411A1 (en) 1996-06-20
JPH10510816A (ja) 1998-10-20
US6281015B1 (en) 2001-08-28
JP4361134B2 (ja) 2009-11-11

Similar Documents

Publication Publication Date Title
ES2176359T3 (es) Liberacion localizada de factores que favorecen la supervivencia de celulas transplantadas.
ES2309849T3 (es) Celulas secretoras macroencapsuladas.
Hill et al. Regulating activation of transplanted cells controls tissue regeneration
US5702444A (en) Implantable artificial endocrine pancreas
Isogai et al. Combined chondrocyte–copolymer implantation with slow release of basic fibroblast growth factor for tissue engineering an auricular cartilage construct
DE69634828D1 (de) Auffindbare künstliche bioimplantate
BR0313726A (pt) Matriz biossintética e empregos desta
DE69526363D1 (de) Modulation von zellproliferation und wundheilung
ES2072563T3 (es) Composicion para el tratamiento cosmetico y/o farmaceutico de las capas superiores de la epidermis por aplicacion topica sobre la piel y procedimiento de preparacion correspondiente.
JP2017080618A5 (es)
NO930713D0 (no) In vivo avgivelse av aktive faktorer ved ko-dyrkete celleimplantater
SV2003000814A (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
Haagdorens et al. In vitro cultivation of limbal epithelial stem cells on surface‐modified crosslinked collagen scaffolds
IL176268A0 (en) Use of alginate matrices to control cell growth
CO5271728A1 (es) Forma de dosificacion de farmaco en capas impulsadas por hidrogel
IT1307829B1 (it) Protesi dentale con mezzi per il rilascio di farmaci o fattorispecifici atti ad impedire l'insorgenza di infezioni e/o promuovere
BRPI0411752A (pt) implantes subcutáneos apresentando liberação inicial limitada do princìpio ativo e liberação ampliada subseqüente linearmente variável do mesmo
ES8706581A1 (es) Un metodo para preparar un dispositivo biomedico conformado
Yang et al. Regenerating hair in prevascularized tissue space formed by a controllable foreign body reaction
Tan et al. The crystallization properties of antifreeze GelMA hydrogel and its application in cryopreservation of tissue‐engineered skin constructs
CN103819694A (zh) 一种具有细胞相容性的丝素蛋白水凝胶及其制备方法
De Castillo et al. Catch in the primary spines of the sea urchin Eucidaris tribuloides: a brief review and a new interpretation
ES2150902T3 (es) Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos.
Dieckmann et al. Human melanocytes can be isolated, propagated and expanded from plucked anagen hair follicles
ES2312508T3 (es) Procedimiento para la preparacion de celulas y tejidos.